The Effect of Bevacizumab (Avastin) on Pterygium

Conditions

• Pterygium

Eligibility Criteria

Sex

ALL

Age

19 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• local injection of bevacizumab — DRUG
  Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.

Study Details

The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.

Key Dates

First listed

Jan 11, 2008

Start date

Aug 31, 2007

Status verified

May 2012

Primary completion

Mar 31, 2010

Completion

Mar 31, 2010

Study Design

Enrollment

5 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Bevacizumab
  Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline

Primary Outcome Measure

The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. [ Time Frame: Baseline and 3 months ]

Locations (1)

Find similar trials in Birmingham, AL